Estimates Revisions Solid Biosciences Inc.
Stocks
SLDB
US83422E2046
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
23:02:00 06/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 6.935 USD | -1.77% |
|
-3.00% | +23.14% |
| 09-16 | Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says | MT |
| 09-16 | RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- SLDB Stock
- Consensus Solid Biosciences Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
